https://lnkd.in/g6N2dDBh Key Insights: • Gilead has expanded its portfolio with the addition of Seladelpar, a PPARδ agonist aimed at treating Primary Biliary Cholangitis (PBC) • Seladelpar is undergoing FDA priority review, with anticipated approval in the U.S. by the third quarter of 2024 Visit MedicoInsights to explore key insights #HealthcareNews #drugs #StayInformed #MedicalNews #HealthTrends #Insights #HealthIndustry #HealthInnovation #gilead #cymabay #acquisition #HealthcareAnalytics #NewsUpdate #HealthcareNetworking #pharma #pharmaceuticals #pharmanews #pharmaindustry #pharmainnovation #update #medicoinsights
MedicoInsights
Technology, Information and Media
Jaipur, Rajasthan 761 followers
Igniting Knowledge Fueling Empowerment
About us
MedicoInsights is your trusted source for the most up-to-date information in the healthcare industry. Our daily reports provide an authoritative spotlight on the dynamic landscape, keeping you informed and empowered in the realm of healthcare evolution Our platform is not just a news hub; it's a beacon of knowledge that illuminates the path to understanding the intricate tapestry of healthcare We go beyond mere reporting, enriching every story with profound insights that bring depth and comprehension to the forefront Mission : To deliver timely, accurate, and comprehensive updates on pharmaceutical advancements and industry, empowering by information and fostering collaboration for a healthier and innovative tomorrow Vision : Transforming through knowledge-sharing, catalyzing innovation, and fostering a holistic ecosystem of medical insights for a healthier and more connected world Goal : Goal of MedicoInsights is to serve as the catalyst for a brighter and more interconnected world of healthcare
- Website
-
https://medicoinsights.com/
External link for MedicoInsights
- Industry
- Technology, Information and Media
- Company size
- 2-10 employees
- Headquarters
- Jaipur, Rajasthan
- Type
- Self-Employed
- Founded
- 2023
- Specialties
- Pharmaceuticals, Health, News, Market Analysis, and Drugs
Locations
-
Primary
Jaipur, Rajasthan 302029, IN
Employees at MedicoInsights
Updates
-
https://lnkd.in/gvrF5MD2 Key Insights: • The approval of Onivyde® regimen (NALIRIFOX) stemmed from the Phase III NAPOLI 3 clinical trial, where it exhibited significant superiority over nab-paclitaxel and gemcitabine, showcasing notable enhancements in overall survival and progression-free survival Visit MedicoInsights to explore key insights #HealthcareNews #drugs #StayInformed #MedicalNews #drugapproval #HealthTrends #Insights #HealthIndustry #HealthInnovation #ipsen #usfda #HealthcareAnalytics #NewsUpdate #HealthcareNetworking #pharma #pharmaceuticals #pharmanews #pharmaindustry #pharmainnovation #update #medicoinsights
Ipsen’s Onivyde®approved by FDA
https://medicoinsights.com
-
https://lnkd.in/dxVqKQG3 Key Insights: • It is the first approved bispecific antibody targeting B-cell maturation antigen (BCMA) on multiple myeloma cells and CD3 on T-cells for immune response activation Visit MedicoInsights to explore key insights #HealthcareNews #drugs #StayInformed #MedicalNews #drugapproval #HealthTrends #Insights #HealthIndustry #HealthInnovation #johnsonandjohnson #usfda #HealthcareAnalytics #NewsUpdate #HealthcareNetworking #pharma #pharmaceuticals #pharmanews #pharmaindustry #pharmainnovation #update #medicoinsights
TECVAYLI® (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA
https://medicoinsights.com
-
https://lnkd.in/dDhpqJCe Key Insights: • VELSIPITY is an oral, once-daily sphingosine 1-phosphate (S1P) receptor modulator that selectively binds with S1P receptor subtypes 1, 4, and 5 • VELSIPITY has received marketing authorization in all 27 EU member states, Iceland, Liechtenstein, and Norway Visit MedicoInsights to explore key insights #HealthcareNews #drugs #StayInformed #MedicalNews #drugapproval #HealthTrends #Insights #HealthIndustry #HealthInnovation #pfizer #fdaapproval #eu #HealthcareAnalytics #NewsUpdate #HealthcareNetworking #pharma #pharmaceuticals #pharmanews #pharmaindustry #pharmainnovation #update #medicoinsights
European Commission Approves Pfizer’s VELSIPITY®
https://medicoinsights.com
-
https://lnkd.in/gNzHgF3c Key Insights: • Targets both RSV and hMPV, surpassing current single-virus RSV vaccines. Phase II results show a 97% strong immune response against RSV and first-ever detection in a combo vaccine for hMPV • Fast Track Designation expedites regulatory review, potentially bringing this impactful vaccine to market sooner Visit MedicoInsights to explore key insights #HealthcareNews #drugs #StayInformed #MedicalNews #drugapproval #HealthTrends #Insights #HealthIndustry #HealthInnovation #astrazeneca #acquisition #partners #icosavax #HealthcareAnalytics #NewsUpdate #HealthcareNetworking #pharma #pharmaceuticals #pharmanews #pharmaindustry #pharmainnovation #update #medicoinsights
AstraZeneca Acquires Icosavax, Bolstering Vaccine Pipeline with RSV and hMPV Candidate
https://medicoinsights.com
-
https://lnkd.in/ggEsXYW3 Key Insights: • Tagrisso with chemo offers a 38% reduction in the risk of disease progression or death compared to standard treatment, providing a significant advantage for patients • The combination offers an 8.8-month increase in median progression-free survival, potentially extending the time patients live without their cancer worsening. This translates to a 53% improvement in PFS compared to Tagrisso alone Visit MedicoInsights to explore key insights #HealthcareNews #drugs #StayInformed #MedicalNews #drugapproval #HealthTrends #Insights #HealthIndustry #HealthInnovation #astrazeneca #anticancer #treatment #partners #HealthcareAnalytics #NewsUpdate #HealthcareNetworking #pharma #pharmaceuticals #pharmanews #pharmaindustry #pharmainnovation #update #medicoinsights
Tagrisso with the addition of chemotherapy approved in the US for patients with EGFR-mutated advanced lung cancer
https://medicoinsights.com
-
https://lnkd.in/gq2GGNC3 Key Insights: • The collaboration aims to utilize the combined expertise and resources of both organizations to develop a safe and effective drug for fungal keratitis • Globally, approximately 1.2 million cases of fungal keratitis are reported annually, with tropical countries experiencing a higher incidence Visit MedicoInsights to explore key insights #HealthcareNews #drugs #StayInformed #MedicalNews #drugapproval #HealthTrends #Insights #HealthIndustry #HealthInnovation #cipla #antifungal #treatment #partners #csir #keratitis #HealthcareAnalytics #NewsUpdate #HealthcareNetworking #pharma #pharmaceuticals #pharmanews #pharmaindustry #pharmainnovation #update #medicoinsights
Cipla partners with CSIR-CDRI to advance Ophthalmic Antifungal Treatment Development
https://medicoinsights.com
-
https://lnkd.in/gQQW2EUQ Key Insights: • Binosto® (buffered soluble alendronate) is approved for treating postmenopausal osteoporosis and is available in Europe, the US, the Middle East, and Asia Visit MedicoInsights to explore key insights #HealthcareNews #drugs #StayInformed #MedicalNews #drugapproval #HealthTrends #Insights #HealthIndustry #HealthInnovation #lupin #distribution #europe #africa #osteoarthritis #menopause #licensing #agreement #HealthcareAnalytics #NewsUpdate #HealthcareNetworking #pharma #pharmaceuticals #pharmanews #pharmaindustry #pharmainnovation #update #medicoinsights
EffRx Pharmaceuticals Signs Exclusive Licensing and Distribution Agreement with Lupin
https://medicoinsights.com
-
https://lnkd.in/gF2ucMrG Key Insights: • Levonorgestrel, ethinyl estradiol, and ferrous bisglycinate combination is utilized as a contraceptive method. This pill contains two hormones, levonorgestrel and ethinyl estradiol, which, when taken correctly, inhibit pregnancy Visit MedicoInsights to explore key insights #HealthcareNews #drugs #StayInformed #MedicalNews #drugapproval #HealthTrends #Insights #HealthIndustry #HealthInnovation #lupin #contraceptive #pills #pregnancy #hormones #HealthcareAnalytics #NewsUpdate #HealthcareNetworking #pharma #pharmaceuticals #pharmanews #pharmaindustry #pharmainnovation #update #medicoinsights
Lupin Receives Approval from U.S. FDA for Minzoya
https://medicoinsights.com
-
https://lnkd.in/gAXGQggN Key Insights: • AMTAGVI is the first and only one-time, personalized T cell therapy to receive FDA approval for solid tumor cancer • It utilizes patient-specific T cells called TIL cells, which are naturally created by the immune system to locate, attack, and destroy cancer cells Visit MedicoInsights to explore key insights #HealthcareNews #drugs #StayInformed #MedicalNews #drugapproval #HealthTrends #Insights #HealthIndustry #HealthInnovation #cancer #tcells #solidtumors #HealthcareAnalytics #NewsUpdate #HealthcareNetworking #pharma #pharmaceuticals #pharmanews #pharmaindustry #pharmainnovation #update #medicoinsights
Iovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval
https://medicoinsights.com